Clinical significance of interleukin-18 and interleukin-10 in patients with chronic obstructive pulmonary disease combined with hypertension
DOI:
https://doi.org/10.14739/2310-1210.2018.5.141530Keywords:
chronic obstructive pulmonary disease, inflammation, interleukin-18, interleukin-10, essential hypertensionAbstract
The problem of chronic obstructive pulmonary disease (COPD) in combination with hypertension (HT) is becoming more relevant because of the growth of its prevalence and adverse consequences in the world as well as in Ukraine.
Aim: To assess the level of interleukin-18 (IL-18) and IL-10 in patients with COPD in combination with HT.
Materials and methods. We examined 87 patients with occupational COPD GOLD 2–3, groups B, C, D. The main group included 67 patients with COPD in combination with HT stage II, the comparison group – 20 patients with COPD. Patients were divided into phenotypes: emphysematous, chronic bronchitic, frequent exacerbator and asthma-COPD overlap syndrome (ACOS) based on the analysis of clinical and anamnestic, anthropometric, spirometric data and chest X-ray examination. The examination was carried out in remission which is characterized by stable clinical symptoms and spirometry indices. General clinical and laboratory examinations, pulse oximetry, pulmonary function test, electrocardiographic, echocardiographic and chest X-ray examinations were performed in all patients. IL-18 and IL-10 in peripheral blood were determined by ELISA using a test system “Bender MedSystems, GmbH” (Austria). The control group included 20 practically healthy age- and gender-matched persons. Statistical analysis of the data was performed using nonparametric statistical methods. The probability of differences in independent groups was estimated using the Mann-Whitney U-criterion. All statistical tests were bilateral, differences were considered significant for P < 0.05.
Results. Analysis of IL-18 levels in patients of the main group, comparison group and control group showed statistically significant differences. The most significant increase in IL-18 level was observed in patients of the main group that was associated with more severe systemic inflammation in COPD combined with HT. The level of IL-10 was significantly increased only in the main group. Patients with COPD GOLD 3, groups C, D and COPD GOLD 2, group B did not significantly differ in IL-18 and IL-10 levels, but there was a tendency to decrease in IL-18 and increase in IL-10 levels in patients with COPD GOLD 3, groups C, D due to initial manifestations of IL-18-mediated proinflammatory response exhaustion. Significant differences between levels of IL-18 and IL-10 in patients with COPD with different phenotypes were revealed. IL-18 levels were elevated in all studied patients, but the degree of increase was quite different. Frequent exacerbators demonstrated blunted IL-18-mediated proinflammatory and excessive anti-inflammatory response.
Conclusions. Cytokine imbalance in patients with COPD in combination with HT determines the course of disease and may be a prognostically significant criterion for consequences of the disease.
References
World Health Organization. Rezhim dostupa: http://www.who.int/respiratory/copd/en/
Bloch, M. J. (2016) Worldwide prevalence of hypertension exceeds 1.3 billion. Journal of the American Society of Hypertension, 10(10), 753–754. doi: 10.1016/j.jash.2016.08.006.
Feary, J. R., Rodrigues, L. C., Smith, C. J., Hubbard, R. B., & Gibson, J. E. (2010) Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax, 65(11), 956–962. doi: 10.1136/thx.2009.128082.
Kim, S. H., Park, J. H., Lee, J. K., Heo, E. Y., Kim, D. K., & Chung, H. S. (2017) Chronic obstructive pulmonary disease is independently associated with hypertension in men. Medicine, 96(19), 1–6. doi: 10.1097/MD.0000000000006826.
Kang, M. J., Choi, J. M., Kim, B. H., Lee, C. M., Cho, W. K., Choe, G., et al. (2012) IL-18 Induces Emphysema and Airway and Vascular Remodeling via IFN-γ, IL-17A, and IL-13. Am. J. Respir. Crit. Care Med, 185(11), 1205–1217. doi: 10.1164/rccm.201108-1545OC.
Boldina, M. V., Postnikova, L. B., Kubysheva, N. I., & Soodaeva, S. K. (2014) Uchastie provospalitel'nykh citokinov IL-17, IL-18 i TNF-a v razvitii narushenij legochnoj i vnutriserdechnoj gemodinamiki pri khronicheskoj obstruktivnoj bolezni legkikh [A role of proinflammatory cytokines IL-17, IL-18 and TNF-α in pulmonary and intracardiac haemodinamic disorders in patients with chronic obstructive pulmonary disease]. Pul'monologiya, 1, 32–37. [in Russian]. doi: 10.18093/0869-0189-2014-0-1-32-37.
Miao, E. A., Rajan, J. V., & Aderem, A. (2011) Caspase-1-induced pyroptotic cell death. Immunol. Rev., 243(1), 206–214. doi: 10.1111/j.1600-065X.2011.01044.x.
Jackson, D. J., Glanville, N., Trujillo-Torralbo, M. B., Shamji, B. W. H., del-Rosario, J., Mallia, P., et al. (2015) Interleukin-18 Is Associated With Protection Against Rhinovirus-Induced Colds and Asthma Exacerbations. Clinical Infectious Diseases, 60(10), 1528–1531. doi: 10.1093/cid/civ062.
Ceballos-Olvera, I., Sahoo, M., Miller, M. A., del Barrio, L., & Re, F. (2011) Inflammasome-dependent Pyroptosis and IL-18 Protect against Burkholderia pseudomallei Lung Infection while IL-1b Is Deleterious. PLoS Pathog, 7(12), e1002452. doi: 10.1371/journal.ppat.1002452.
Maneechotesuwan, K., Wongkajornsilp, A., Adcock, I. M., & Barnes, P. J. (2015) Simvastatin Suppresses Airway IL-17 and Upregulates IL-10 in Patients With Stable COPD. CHEST, 148(5), 1164–1176. doi: 10.1378/chest.14-3138.
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
